Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 946-952

  Alupei, Marius Costel ^a   Licarete, Emilia ^a   Patras, Laura ^a   Banciu, Manuela ^a  

^a BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

Cancer; Lipophilic statin; Liposomes; Oxidative stress; Tumor associated macrophages

Indexed keywords

CLODRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; PRAVASTATIN; SIMVASTATIN; CATALASE; HIF1A PROTEIN, MOUSE; MALONALDEHYDE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ENCAPSULATION; MELANOMA; MOUSE; NONHUMAN; OXIDATIVE STRESS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; MACROPHAGE; MALE; MELANOMA, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL CULTURE; VASCULARIZATION; WESTERN BLOTTING;

MURINAE;

ANIMALS; BLOTTING, WESTERN; CATALASE; CELL PROLIFERATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOSOMES; MACROPHAGES; MALE; MALONDIALDEHYDE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OXIDATIVE STRESS; SIMVASTATIN; TUMOR CELLS, CULTURED;

EID: 84919430026     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.010     Document Type: Article

References (35)

1. Qi X.F., Kim D.H., Yoon Y.S., Kim S.K., Cai D.Q., Teng Y.C., et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol. Lett 2010, 199:277-287.
2. Yilmaz M.I., Baykal Y., Kilic M., Sonmez A., Bulucu F., Aydin A., et al. Effects of statins on oxidative stress. Biol. Trace Elem. Res 2004, 98:119-127.
3. Coleman M.L., Olson M.F. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 2002, 9:493-504.
4. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol 2005, 45:89-118.
5. Bar-Sagi D., Hall A. Ras and Rho GTPases: a family reunion. Cell 2000, 103:227-238.
6. Eto M., Barandier C., Rathgeb L., Kozai T., Joch H., Yang Z., et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res 2001, 89:583-590.
7. Laufs U., Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med 2000, 10:143-148.
8. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
9. Banciu M., Metselaar J.M., Schiffelers R.M., Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 2008, 10:108-117.
10. Schiffelers R.M., Metselaar J.M., Fens M.H., Janssen A.P., Molema G., Storm G. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 2005, 7:118-127.
11. Afergan E., Ben David M., Epstein H., Koroukhov N., Gilhar D., Rohekar K., et al. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J. 2010, 12:181-187.
12. Briggs A.P. Some applications of the colorimetric phosphate method. J. Biol. Chem 1924, 59:255-264.
13. Sultana N., Arayne M.S., Naz Shah S., Shafib N., Naveed S. Simultaneous Determination of prazosin, atorvastatin, rosuvastatin and simvastatin in API, dosage formulations and human serum by RP-HPLC. J. Chin. Chem. Soc 2010, 57:1286-1292.
14. Kenny A.P. The determination of cholesterol by the Liebermann-Burchard reaction. Biochem. J. 1952, 52:611-619.
15. Coimbra M., Banciu M., Fens M.H., de Smet L., Cabaj M., Metselaar J.M., et al. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J. Control. Release 2010, 148:303-310.
16. Alupei M.C., Licarete E., Cristian F.B., Banciu M. Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1alpha expression and redox status in B16.F10 melanoma cells. Anticancer Drugs 2014, 25:393-405.
17. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem 1949, 177:751-766.
18. Banciu M., Schiffelers R.M., Fens M.H., Metselaar J.M., Storm G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J. Control. Release 2006, 113:1-8.
19. Karatas F., Karatepe M., Baysar A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography. Anal. Biochem 2002, 311:76-79.
20. Aysegul A.Y., Sebnem G., Sibel D., Ahmet E.Y., Gulay I.Y. Comparison of two different applications of the Griess method for nitric oxide measurement. J. Exp. Integr. Med 2012, 2:167-171.
21. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem 1982, 126:131-138.
22. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
23. Ratajczak-Wrona W., Jablonska E., Antonowicz B., Dziemianczyk D., Grabowska S.Z. Levels of biological markers of nitric oxide in serum of patients with squamous cell carcinoma of the oral cavity. Int. J. Oral. Sci 2013, 5:141-145.
24. Banciu M., Fens M.H., Storm G., Schiffelers R.M. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. J. Control. Release 2008, 127:131-136.
25. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res 2001, 7:223-225.
26. Weis M., Heeschen C., Glassford A.J., Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739-745.
27. Fruehauf J.P., Trapp V. Reactive oxygen species: an Achilles' heel of melanoma?. Expert Rev. Anticancer Ther 2008, 8:1751-1757.
28. Joosse A., De Vries E., van Eijck C.H., Eggermont A.M., Nijsten T., Coebergh J.W. Reactive oxygen species and melanoma: an explanation for gender differences in survival?. Pigment Cell Melanoma Res 2010, 23:352-364.
29. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327.
30. Brown G.C. Reversible binding and inhibition of catalase by nitric oxide. Eur. J. Biochem 1995, 232:188-191.
31. Huang K.C., Chen C.W., Chen J.C., Lin W.W. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J. Biomed. Sci 2003, 10:396-405.
32. Mills C.N., Joshi S.S., Niles R.M. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol. Cancer 2009, 8:104.
33. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol 2001, 13:167-171.
34. Qutub A.A., Popel A.S. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol. Cell. Biol 2008, 28:5106-5119.
35. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2784-2789.